On Sunday, Brazil received the first doses of the Oxford/AstraZeneca vaccine delivered by the United Nations‘ Covax Facility. Bolivia, Nicaragua and Colombia also received doses via Covax.
Good news for Latin America, as a U.S. trial of AstraZeneca and Oxford‘s coronavirus vaccine said on Monday that it provided 79% efficacy at preventing symptomatic cases and 100% efficacy against severe or critical conditions of COVID-19. The immunizer also showed 80% efficacy in participants aged 65 years and over.
Besides, according to the pharmaceutical firm, “the independent data safety monitoring board found no increased risk of thrombosis or events characterized by thrombosis among the 21,583 participants receiving at least one dose of the vaccine. The specific search for cerebral venous sinus thrombosis found no events in this trial.”
So far, Brazil received 1 million doses of AstraZeneca’s immunizer via Covax, and it is expected to receive 1.9 million more by the end of March.